Get startedLog in
    Picture of Novo Nordisk A/S logo

    NOVO B — Novo Nordisk A/S News Story

    0.000.00%
    dk flag iconLast trade - 00:00
    HealthcareSpeculativeLarge CapNeutral
    All News

    Brief: Novo Real-World Studies Link Wegovy 2.4 MG To Reductions In Liver Enzymes, Weight, Blood Sugar In Adults With Mash

    Picture of Novo Nordisk A/S logoNovo Nordisk A/S
    06/11/2026 20:19
    BRIEF-Novo Real-World Studies Link Wegovy 2.4 MG To Reductions In Liver Enzymes, Weight, Blood Sugar In Adults With Mash
    Nov 7 (Reuters) - Novo Nordisk A/S NOVOb.CO:
    • NOVO:  NOVO REAL-WORLD STUDIES LINK WEGOVY 2.4 MG TO REDUCTIONS IN LIVER ENZYMES, WEIGHT, AND BLOOD SUGAR IN ADULTS WITH MASH - WEBSITE
    • NOVO: SEMAGLUTIDE 2.4 MG WAS ALSO ASSOCIATED WITH SIGNIFICANTLY GREATER REDUCTIONS THAN RESMETIROM IN AST & SOME CARDIOMETABOLIC MEASURES
    • NOVO: DATA FROM SEPARATE ANALYSIS SHOWS SEMAGLUTIDE 2.4 MG INITIATORS HAD GREATER 1-YEAR REDUCTIONS IN LIVER ENZYMES, WEIGHT VERSUS NON-INITIATORS

    Further company coverage: [NOVOb.CO]

     ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Novo Nordisk A/S

    See all news